03.04 Targeted disruption of tumor-borne GDF-15-mediated immunoresistance restores immune checkpoint inhibitor activity in last-line cancer patients

• T Ross,
• M KIST,
• M Haake,
• N Vashist,
• K Eichler,
• S Genßler,
• I Giese,
• J Weigandt,
• K Klar,
• P Fettes,
• J Wischhusen,
• E Leo,
• C Schuberth-Wagner

Affiliations

T Ross

Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

M KIST

1CatalYm GmbH, Planegg-Martinsried, Germany

M Haake

1CatalYm GmbH, Planegg-Martinsried, Germany

N Vashist

1CatalYm GmbH, Planegg-Martinsried, Germany

K Eichler

1CatalYm GmbH, Planegg-Martinsried, Germany

S Genßler

1CatalYm GmbH, Planegg-Martinsried, Germany

I Giese

1CatalYm GmbH, Planegg-Martinsried, Germany

J Weigandt

1CatalYm GmbH, Planegg-Martinsried, Germany

K Klar

1CatalYm GmbH, Planegg-Martinsried, Germany

P Fettes

1CatalYm GmbH, Planegg-Martinsried, Germany

J Wischhusen

2Würzburg University Hospital, University of Würzburg, Würzburg, Germany

E Leo

1CatalYm GmbH, Planegg-Martinsried, Germany

C Schuberth-Wagner

1CatalYm GmbH, Planegg-Martinsried, Germany